Daniela Purcea

735 total citations
15 papers, 244 citations indexed

About

Daniela Purcea is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniela Purcea has authored 15 papers receiving a total of 244 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniela Purcea's work include Cancer Immunotherapy and Biomarkers (4 papers), Hormonal and reproductive studies (3 papers) and Prostate Cancer Treatment and Research (3 papers). Daniela Purcea is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Hormonal and reproductive studies (3 papers) and Prostate Cancer Treatment and Research (3 papers). Daniela Purcea collaborates with scholars based in Switzerland, France and United States. Daniela Purcea's co-authors include Pierre Grosgurin, Dieter Häussinger, R. Crabbé, Elisabeth Rouits, Petre Iacob Calistru, G. Vuagniaux, Carlos Gomez‐Roca, G. Mazzella, Wiesław Kryczka and Jean–Michel Pawlotsky and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Hepatology.

In The Last Decade

Daniela Purcea

15 papers receiving 238 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniela Purcea Switzerland 10 87 69 47 46 42 15 244
Veronika Kanitz Germany 8 69 0.8× 16 0.2× 51 1.1× 24 0.5× 74 1.8× 9 264
Senlin Zhu China 11 134 1.5× 63 0.9× 27 0.6× 22 0.5× 59 1.4× 31 321
Mina Farag Canada 9 188 2.2× 117 1.7× 99 2.1× 67 1.5× 38 0.9× 23 339
Elena Wiese Germany 8 88 1.0× 21 0.3× 117 2.5× 11 0.2× 29 0.7× 15 298
JH Kim South Korea 7 63 0.7× 24 0.3× 81 1.7× 9 0.2× 95 2.3× 18 311
Verena Wagner Germany 6 70 0.8× 45 0.7× 23 0.5× 9 0.2× 51 1.2× 12 199
Ryo Ichikawa Japan 7 33 0.4× 42 0.6× 49 1.0× 34 0.7× 70 1.7× 17 237
R Okuyama Japan 5 34 0.4× 8 0.1× 22 0.5× 18 0.4× 85 2.0× 6 345
Anbin Hu China 10 56 0.6× 23 0.3× 50 1.1× 132 2.9× 51 1.2× 33 254
Shili Qiu China 9 312 3.6× 24 0.3× 51 1.1× 22 0.5× 26 0.6× 10 469

Countries citing papers authored by Daniela Purcea

Since Specialization
Citations

This map shows the geographic impact of Daniela Purcea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Purcea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Purcea more than expected).

Fields of papers citing papers by Daniela Purcea

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Purcea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Purcea. The network helps show where Daniela Purcea may publish in the future.

Co-authorship network of co-authors of Daniela Purcea

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Purcea. A scholar is included among the top collaborators of Daniela Purcea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Purcea. Daniela Purcea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Galsky, Matt D., Guru Sonpavde, Thomas Powles, et al.. (2024). Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.. Journal of Clinical Oncology. 42(16_suppl). 4509–4509. 11 indexed citations
2.
Heijden, Michiel S. van der, Guru Sonpavde, Thomas Powles, et al.. (2023). LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial. Annals of Oncology. 34. S1341–S1341. 9 indexed citations
3.
Gomez‐Roca, Carlos, Caroline Even, Christophe Le Tourneau, et al.. (2021). Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer. Clinical and Translational Science. 15(1). 55–62. 17 indexed citations
4.
5.
Gelderblom, Hans, Jourik A. Gietema, Ingrid M.E. Desar, et al.. (2020). 601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours. Annals of Oncology. 31. S501–S502. 5 indexed citations
6.
Juergens, Rosalyn A., Quincy S. Chu, Daniel J. Renouf, et al.. (2019). A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.. Journal of Clinical Oncology. 37(15_suppl). 2599–2599. 6 indexed citations
7.
Voss, Martin H., Cinta Hierro, Rebecca S. Heist, et al.. (2017). Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 2500–2500. 11 indexed citations
8.
Breul, Jürgen, et al.. (2016). Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer. Advances in Therapy. 34(2). 513–523. 16 indexed citations
9.
Klein, Karen O., Joshua Yang, Javier Aisenberg, et al.. (2016). Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. Journal of Pediatric Endocrinology and Metabolism. 0(0). 1241–1248. 31 indexed citations
10.
Isambert, Nicolás, Jean‐Pierre Delord, Jean‐Charles Soria, et al.. (2015). Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase. Annals of Oncology. 26(5). 1005–1011. 27 indexed citations
11.
Nicolas‐Métral, Valerie, Anne Vaslin, Jeffrey G. Supko, et al.. (2015). Abstract CT228: Formulation switch and pharmacokinetics/pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor, in a first-in-human dose escalation trial in solid tumors patients. Cancer Research. 75(15_Supplement). CT228–CT228. 3 indexed citations
12.
Ray‐Coquard, Isabelle, Christophe Le Tourneau, Nicolás Isambert, et al.. (2015). Abstract C2: Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study. Molecular Cancer Therapeutics. 14(12_Supplement_2). C2–C2. 2 indexed citations
13.
Flisiak, Robert, Jean–Michel Pawlotsky, R. Crabbé, et al.. (2011). 4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS. Journal of Hepatology. 54. S2–S2. 46 indexed citations
14.
Mounedji, Nadjat, et al.. (2011). Efficacy of triptorelin in lowering serum testosterone (sT) in patients with advanced prostate cancer.. Journal of Clinical Oncology. 29(7_suppl). 162–162. 9 indexed citations
15.
Rencken, Rupert K., Simon Reif, A. R. Pontin, et al.. (2009). Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer. Clinical Drug Investigation. 29(12). 757–765. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Veronika Kanitz Breakdown of academic impact, for papers by Senlin Zhu Breakdown of academic impact, for papers by Mina Farag Breakdown of academic impact, for papers by Elena Wiese Breakdown of academic impact, for papers by JH Kim Breakdown of academic impact, for papers by Verena Wagner Breakdown of academic impact, for papers by Ryo Ichikawa Breakdown of academic impact, for papers by R Okuyama Breakdown of academic impact, for papers by Anbin Hu Breakdown of academic impact, for papers by Shili Qiu
Rankless by CCL
2026